Holen Sie sich die Stockscreener-App
6.09
1.14%
-0.07
Vorhandelsmarkt:
6.11
0.02
+0.33%
Schlusskurs vom Vortag:
$6.16
Offen:
$6.09
24-Stunden-Volumen:
663.00K
Relative Volume:
0.60
Marktkapitalisierung:
$253.30M
Einnahmen:
$134.48M
Nettoeinkommen (Verlust:
$-38.94M
KGV:
-6.3877
EPS:
-0.9534
Netto-Cashflow:
$-19.34M
1W Leistung:
-13.12%
1M Leistung:
+8.56%
6M Leistung:
-29.43%
1J Leistung:
-27.93%
1-Tages-Spanne:
$5.945
$6.245
1-Wochen-Bereich:
$5.945
$7.095
52-Wochen-Spanne:
$4.48
$13.22
Rxsight Inc Stock (RXST) Company Profile
Firmenname
Rxsight Inc
Sektor
Branche
Telefon
949-521-7822
Adresse
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
6.09 | 256.21M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
114.14 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
327.70 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.30 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.37 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.83 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Eingeleitet | William Blair | Mkt Perform |
| 2025-07-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Herabstufung | Jefferies | Buy → Hold |
| 2025-07-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Eingeleitet | Piper Sandler | Neutral |
| 2025-04-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-04-04 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-10-29 | Eingeleitet | Jefferies | Buy |
| 2024-08-20 | Bestätigt | Needham | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-05-07 | Bestätigt | BTIG Research | Buy |
| 2023-12-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
Alle ansehen
Rxsight Inc Aktie (RXST) Neueste Nachrichten
Tocqueville Asset Management L.P. Makes New Investment in RxSight, Inc. $RXST - MarketBeat
Steven Cohen’s Point72 discloses RxSight (RXST) stake - Stock Titan
RxSight (RXST) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison at the Close; Price Move - Vinanet
RxSight (RXST) Market: Moves 1.88% Higher to $6.49 in the Current Update; Boundary Watch: Support at $6.17 and Resistance at $6.81 Frame the Range on the DayATR Trailing Stop - Vinanet
Vitruvian Partners LLP Purchases New Holdings in RxSight, Inc. $RXST - MarketBeat
RxSight (RXST) Quarterly Figures: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Price Reaction: The Stock Ends Down 1.70% in the Latest SessionGuidance Upgrade Report - Vinanet
RxSight (NASDAQ: RXST) ex-director to sell 11,890 shares - Stock Titan
Midday Stock Roundup: Eledon Falls 3.5% - Orange County Business Journal
RxSight (RXST) Close and Levels: Loses 2.31% to Close at $6.33 on the Day; Trading Range: Support at $6.01 and Resistance at $6.65 Frame the Range in the Available RecordAnchored VWAP - Vinanet
RxSight Inc. (RXST) Drops Nearly 6% as Shares Approach Key SupportMcClellan Summation - Vinanet
RxSight (RXST) Slips to $6.89 as Bearish Momentum Builds in Medical Device StockRVOL Spike - Vinanet
Walleye Capital LLC Takes Position in RxSight, Inc. $RXST - MarketBeat
RxSight, Inc. (NASDAQ:RXST) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery? - Yahoo Finance
RxSight (RXST) Q2 2026 Earnings Call Transcript - AOL.com
(RXST) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Azalea Vision Appoints Co-Founder Andrés Vasquez Quintero as Chief Executive Officer to Lead Next Phase of Clinical Development - AOL.com
Rxsight Inc (RXST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alcon Q2 Sales Rise on Strength in Vision Care, Surgical Segments - VisionMonday.com
Eye care company Alcon raises margin outlook, shares jump - marketscreener.com
Stifel cuts RxSight stock price target on competitive headwinds By Investing.com - Investing.com India
RxSight Inc. (RXST) PT Lowered to $7 at Stifel Amid U.S. Adoption Challenges - StreetInsider
Stifel Nicolaus Lowers RxSight (NASDAQ:RXST) Price Target to $7.00 - MarketBeat
Stifel cuts RxSight stock price target on competitive headwinds - Investing.com
RxSight (RXST) offers to swap 4.08M underwater options for new awards - Stock Titan
Stifel Maintains RxSight(RXST.US) With Hold Rating, Cuts Target Price to $7 - Moomoo
RxSight Reports Q2 Financial Results, Provides Update on 2026 Outlook - VisionMonday.com
The RxSight, Inc. (NASDAQ:RXST) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - 富途牛牛
Wall Street Zen Upgrades RxSight (NASDAQ:RXST) to Hold - MarketBeat
Levi & Korsinsky Notifies RxSight, Inc. (RXST) InvestorsLead Plaintiff Deadline on September 22, 2025 - The National Law Review
Rxsight Inc (RXST) Stock News Today - TradingKey
A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $6 to $11 - moomoo.com
UBS Maintains RxSight(RXST.US) With Hold Rating, Cuts Target Price to $6.3 - Moomoo
UBS Group Boosts RxSight (NASDAQ:RXST) Price Target to $6.30 - MarketBeat
Earnings To Watch: RxSight Inc (RXST) Q2 2026 -- GF Value Sees 5 - GuruFocus
Earnings To Watch: RxSight Inc (RXST) Q2 2026 -- GF Value Sees 519% Upside - Yahoo Finance
RxSight, Inc. Stock 12‑Month Price Target Cut to $7.91, Implies 26% Upside - TradingView
A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $9 to $11 - moomoo.com
Rxsight, Inc. Reports Second Quarter 2026 Res - Moomoo
RxSight Q2 Earnings Call Highlights - MarketBeat
RxSight Inc (RXST) (Q2 2026) Earnings Call Highlights: Strategic Pivot Amid Revenue Decline and ... - finance.yahoo.com
RxSight (NASDAQ:RXST) Releases Earnings Results, Beats Estimates By $0.22 EPS - MarketBeat
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates - finance.yahoo.com
RxSight, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
RXST: Q2 revenue was $33.7M, guidance withdrawn as business undergoes strategic reassessment - TradingView
Earnings call transcript: RxSight beats Q2 2026 estimates but withdraws guidance - Investing.com
Transcript : RxSight, Inc., Q2 2026 Earnings Call, Aug 05, 2026 - marketscreener.com
RxSight Q2 adjusted loss beats estimates; withdraws 2026 guidance - TradingView
RxSight (RXST) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
RxSight, Inc. (RXST) Tops Q2 EPS by 25c - StreetInsider
RxSight, Inc. Q2 2026: Revenue $33.74M, EPS $(0.29) — 10-Q Summary - TradingView
Finanzdaten der Rxsight Inc-Aktie (RXST)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):